Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a quicker, cheaper scan replace the gold standard for heart blood flow?

NCT ID NCT07708805

Diagnosis Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study explores whether a newer type of SPECT/CT scan can accurately measure blood flow in the heart, similar to the more expensive and less available PET scan. Researchers will compare the two imaging methods in 30 adults with coronary artery disease who are already scheduled for heart testing. If SPECT/CT proves reliable, it could offer a simpler, faster, and more accessible option for assessing heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could make advanced heart blood-flow testing more widely available and less expensive.
What could go wrong
This is a small, early feasibility study, so results may not confirm that SPECT/CT can reliably replace PET in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant has provided informed consent to participate in the study. 2. Age ≥ 18 years. 3. Patients referred for functional cardiac imaging assessment (SPECT or PET) following diagnostic coronary CT angiography (CCTA) or invasive coronary angiography demonstrating either: * moderate coronary atherosclerosis without significant coronary stenosis (\<50% stenosis), or * coronary lesions for which functional cardiac imaging assessment or medical therapy is indicated. Exclusion Criteria: 1. Severe coronary artery disease requiring prompt revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), including left main coronary artery stenosis \>50% or other severe coronary lesions with FFR \<0.80. 2. History of coronary revascularization (PCI, coronary stenting, or CABG). 3. Left ventricular ejection fraction (LVEF) \<35%. 4. Contraindication to pharmacological stress testing for cardiac PET/SPECT, including severe hypotension, second- or third-degree atrioventricular block, or recent myocardial infarction. 5. Protected adult under legal guardianship or curatorship. 6. Individual under judicial protection measures. 7. Individual deprived of liberty. 8. Individual not affiliated with a health insurance 9. Pregnant or breastfeeding woman.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic coronary syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic coronary syndrome Coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire d'Orléans

    Orléans, Loiret, 45067, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.